多基因对抗抑郁药不响应单极抑郁症患者的增强结果的贡献
Julia Kraft1,2,3, Pichit Buspavanich1,4,5,6, Alice Braun1,2,3
1Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Mitte, Berlin, Germany.
medRxiv : the preprint server for health sciences
|February 20, 2025
概括
患双相情感障碍多基因风险较高,患重度抑郁症风险较低的个体在增强后表现更好. 多基因风险评分可以帮助预测抑郁症治疗反应.
科学领域:
- 精神病学是一个精神病学.
- 遗传学 遗传学 是一个
- 药物基因组学 药物基因组学
背景情况:
- 增强 (LA) 对于严重抑郁症是有效的,但反应各不相同.
- 预测LA结果对于个性化治疗至关重要.
- 多基因风险评分 (PRS) 可能为治疗预测提供见解.
研究的目的:
- 调查PRS对精神分裂症 (SCZ),主要抑郁症 (MDD) 和双相情感障碍 (BIP) 对MDD患者LA后临床结果的影响.
- 探索PRS在预测LA的反应和缓解率方面的潜力.
主要方法:
- 使用GWAS总结统计数据在193名患有不充分抗抑郁药反应的MDD患者中构建了特定疾病的PRS.
- 在四周或更长时间内使用汉密尔顿抑郁评分表 (HAMD) 评估抑郁症状.
- 使用考克斯比例危险回归模型估计的响应和缓解的危险比率.
主要成果:
- 双极性障碍PRS (BIP-PRS) 与LA后的反应 (HR=1.29) 和缓解 (HR=1.52) 有积极的关联.
- 对于MDD,较低的多基因负担与更好的LA反应相关 (HR=0.81).
- 在SCZ-PRS和临床结果之间没有发现显著的关联.
结论:
- 较高的BIP-PRS和较低的MDD-PRS预测了从LA受益的可能性更大.
- 在单极性抑郁症中,PRS可以作为LA结果的预测生物标志物.
- 复制研究是必要的,以验证临床预测模型的PRS.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
181
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
181
Mania and Antimanic Drugs: Overview
115
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
115
Human Genetics
522
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
522
Long-term Depression
30.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
30.5K
Psychosis: Goals of Pharmacotherapy
102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
Antidepressant Drugs: Overview
351
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
351


